The delivery of drugs to brain tumors is limited by the presence of the blood–brain barrier
(BBB) separating the blood from the cerebral parenchyma. An understanding of the specific …

Among the challenges to the 21st-century health care industry, one that demands special
mention is the transport of drugs/active pharmaceutical agents across the blood–brain …

A great challenge to clinical development is the delivery of chemotherapeutic agents, known
to cause severe toxic effects, directly to diseased sites which increase the therapeutic index …

There are many problems directly correlated with the systemic administration of drugs and
how they reach their target site. Targeting promises to be a hopeful strategy as an improved …

Multimodal combinations of target agents with radiation and chemotherapy may enhance
cancer treatment efficacy; however, despite these treatments, gliomas recur early due to …

The progressive production and subsequent accumulation of β-amyloid (Aβ), a proteolytic
fragment of the membrane-associated amyloid precursor protein (APP), plays a central role …

Edelfosine is the prototype molecule of a family of anticancer drugs collectively known as
synthetic alkyl-lysophospholipids. This drug holds promise as a selective antitumor agent …

Aim: The aim of this work was to investigate the effect of surface modification of
biodegradable nanoparticles on their cellular uptake, cytotoxicity and biodistribution for the …

The aim of this study was to investigate the brain targeting potential of rasagiline-
encapsulated chitosan-coated PLGA nanoparticles (RSG-CS-PLGA-NPs) delivered …

Glioma has been considered to be the most frequent primary tumor within the central
nervous system (CNS). The complexity of glioma, especially the existence of the blood-brain …